English Journal

Genetic polymorphisms of human UDP-glucuronosyltransferase (UGT) genes and cancer risk.

Hu DG1, Mackenzie PI1, McKinnon RA1, Meech R1.
Drug metabolism reviews.Drug Metab Rev.2016 Feb 1:1-19. [Epub ahead of print]
Identification of genetic polymorphisms that contribute to the risk of developing cancers is important for cancer prevention. The most recent human genome GRCh38/hg38 assembly (2013) reveals thousands of genetic polymorphisms in human uridine diphosphoglucuronosyltransferase (UGT) genes. Among these
PMID 26828111

Fay MJ1, Nguyen MT1, Snouwaert JN1, Dye R1, Grant DJ1, Bodnar WM1, Koller BH2.
Drug metabolism and disposition: the biological fate of chemicals.Drug Metab Dispos.2015 Dec;43(12):1838-46. doi: 10.1124/dmd.115.065482. Epub 2015 Sep 9.
UDP-Glucuronosyltransferases (UGTs) conjugate a glucuronyl group from glucuronic acid to a wide range of lipophilic substrates to form a hydrophilic glucuronide conjugate. The glucuronide generally has decreased bioactivity and increased water solubility to facilitate excretion. Glucuronidation repr
PMID 26354949

Human UDP-Glucuronosyltransferases: Effects of altered expression in breast and pancreatic cancer cell lines.

Dates CR1, Fahmi T, Pyrek SJ, Yao-Borengasser A, Borowa-Mazgaj B, Bratton SM, Kadlubar SA, Mackenzie PI, Haun RS, Radominska-Pandya A.
Cancer biology & therapy.Cancer Biol Ther.2015;16(5):714-23. doi: 10.1080/15384047.2015.1026480.
Increased aerobic glycolysis and de novo lipid biosynthesis are common characteristics of invasive cancers. UDP-glucuronosyltransferases (UGTs) are phase II drug metabolizing enzymes that in normal cells possess the ability to glucuronidate these lipids and speed their excretion; however, de-regulat
PMID 25996841